Incyte Corporation

Stocks

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2026 BST			5-day change	1st Jan Change
116.71 ^USD	-1.53%		-0.13%	+18.16%

07-07	RBC Capital Adjusts Incyte Price Target to $99 From $95, Maintains Sector Perform Rating	MT
07-06	Incyte Corporation completed the acquisition of Vega Therapeutics, Inc. from Star OpCo, Inc.	CI

Published on 05/19/2026 at 04:35 pm BST - Modified on 05/19/2026 at 06:35 pm BST

S&P Capital IQ

Presenter Speech
Brian Abrahams (Analysts)

[Audio Gap] featured company Incyte, presented by their Chief Medical Officer, Steven Stein. So thanks so much for joining us, Steven.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

07-07	RBC Capital Adjusts Incyte Price Target to $99 From $95, Maintains Sector Perform Rating	MT
07-06	Incyte Corporation completed the acquisition of Vega Therapeutics, Inc. from Star OpCo, Inc.	CI
06-30	FDA clears Orca's blood cancer therapy to reduce stem cell transplant complications	RE
06-29	Incyte Corporation(NasdaqGS:INCY) dropped from Russell Midcap Growth Benchmark	CI
06-29	Incyte Corporation(NasdaqGS:INCY) dropped from Russell 3000E Growth Benchmark	CI
06-29	Incyte Corporation(NasdaqGS:INCY) dropped from Russell 1000 Growth Benchmark	CI
06-29	Incyte Corporation(NasdaqGS:INCY) dropped from Russell 1000 Growth-Defensive Index	CI
06-28	Incyte Corporation(NasdaqGS:INCY) dropped from Russell 1000 Dynamic Index	CI
06-28	Incyte Corporation(NasdaqGS:INCY) dropped from Russell 3000 Growth Benchmark	CI
06-26	European Medicines Agency Panel Backs Label Expansion for Incyte's Opzelura	MT
06-26	UBS Adjusts Price Target on Incyte to $113 From $103, Maintains Neutral Rating	MT
06-26	Incyte Receives Positive Chmp Opinion for Opzelura (Ruxolitinib) Cream for Treatment of Moderate Atopic Dermatitis in Adults	CI
06-26	Incyte's Opzelura Advances Toward EU Approval for Atopic Dermatitis	MT
06-25	UBS Adjusts Price Target on Incyte to $113 From $103	MT
06-22	Truist Securities Raises Incyte Price Target to $105 From $103, Hold Rating Kept	MT